Related Experiment Videos
New prospects for lipid-lowering drugs
1MRC Lipoprotein Team, Clinical Sciences Centre, Imperial College School of Medicine, London, UK.
Expert Opinion on Investigational Drugs
|July 5, 2005
Summary
New lipid-modulating drugs are being developed to treat dyslipidemia and prevent atherosclerosis. While statins are effective, research continues on novel inhibitors targeting cholesterol synthesis and transport.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism Research
Background:
- 3-hydroxy-methylglutaryl Co-enzyme A (HMG-CoA) reductase inhibitors (statins) have revolutionized dyslipidemia treatment and atherosclerosis prevention.
- Older drugs like fibrates and bile acid sequestrants remain in use, with fibrates showing potential through peroxisome proliferator activated receptors (PPARs).
Purpose of the Study:
- To review the current landscape and future directions in the development of lipid-modulating drugs.
- To highlight the ongoing emphasis on lowering low-density lipoprotein (LDL) cholesterol.
Main Methods:
- Review of existing and emerging drug classes for dyslipidemia.
- Discussion of compounds in clinical trials and earlier stages of development.
Main Results:
- HMG-CoA reductase inhibitors and bile acid sequestrants dominate current clinical trials.
- Emerging drug targets include squalene synthase, acylcholesterolacyltransferase (ACAT), and microsomal triglyceride transfer protein (MTP).
Conclusions:
- Despite the success of statins, the field of lipid-modulating drug development remains dynamic.
- Newer agents targeting ACAT and MTP show promise but face challenges like bioavailability and safety concerns.